Business Wire

Elon Musk Talks ‘Tech Support’ Governance as World Leaders Champion Innovation-Driven Reforms at Dubai Summit

14.2.2025 16:57:00 CET | Business Wire | Press release

Share

Wearing a “Tech Support”-printed T-shirt, Elon Musk virtually took to the stage on the final day of the World Governments Summit in a live discussion with H.E. Omar Sultan Al Olama, UAE Minister of State for Artificial Intelligence, Digital Economy, and Remote Work Applications, to share his vision for improving government efficiency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214293771/en/

Elon Musk in conversation with H.E. Omar Sultan Al Olama, UAE Minister of State for Artificial Intelligence, Digital Economy, and Remote Work Applications (Photo: Business Wire)

Musk emphasized the urgency of streamlining operations, advocating for smaller, more accountable institutions to drive efficiency and economic growth.

The World Governments Summit, held in Dubai from February 11-13, brought together global leaders and experts to address critical challenges in governance, healthcare, and trade in the 21st century.

Now in its 12th edition, the Summit unveiled a suite of insights, key results, and actionable solutions developed by top policymakers, innovators, and thought leaders from around the world.

Musk stated: “We have the rule of bureaucracy as opposed to the rule of the people” and advocated for cutting regulations and government spending to stimulate economic growth, aiming for 4-5% growth without inflation by 2026.

“The overarching goal is to lay the foundation for prosperity that will last many decades, maybe centuries,” Musk added. He stressed the importance of updating government technology, noting that many systems are outdated and inefficient, such as the manual pension system. “The U.S. government needs tech support,” he quipped.

On foreign policy, Musk stated, “America should mind its own business rather than push for regime change,” signaling a shift towards less international interference. He also stressed the need to improve basic education, pointing out the U.S.’s low ranking in the OECD.

Musk also discussed Grok 3.0, his latest AI model set to launch in 1-2 weeks, calling it “scary smart.” He added, “This might be the last time any AI is better than Grok.”

Meanwhile, Joseph Tsai, Chairman of Alibaba Group, a user and admirer of Grok, argued that the value of AI isn’t in having the smartest systems, but in their application in solving real-world problems.

He compared AI development to raising children, emphasizing that not everyone needs the “smartest child.” He predicts that more resources will shift towards practical applications, leveraging open-source tools, which democratize AI development. He added: “Companies big and small can now develop AI together and contribute to the power of AI.”

Beyond AI, both Arvind Krishna, CEO of IBM, and Sundar Pichai, CEO of Google, said they looked forward to the imminent age of quantum computing, which they believe will spearhead the world into a new era.

Pichai said: “Google’s quantum computing performed a computation in five minutes that would take the fastest supercomputer over 10 septillion years.” He compared its current state to AI in the 2010s, predicting practical applications within 5-10 years.

Pichai added that for governments: “It’s too early to regulate the technology, but I think it’s important to come to a good understanding of it and then start preparing for it.”

Technology as the enabler of the new age of healthcare and education

Public healthcare systems also require innovation and new policies, argued experts at the Summit. Addressing key challenges in healthcare, Pascal Soriot, CEO of AstraZeneca, encouraged governments to develop policies that enable early disease diagnostics, improve accessibility, and encourage population-wide adoption.

Soriot stated: “Seventy-five percent of deaths come from diseases that are preventable, yet governments only spend 3% of healthcare budgets on prevention and early diagnosis.” He added that diagnostic centers should run 24/7 to reduce costs and increase accessibility.

He highlighted AI’s role in transforming healthcare, noting that it is already enhancing early diagnostics, such as lung cancer detection from X-rays, and improving efficiency in drug development. While skepticism exists around AI's role in drug design due to limited biological data, its potential in healthcare is promising.

“We are not far away from the days when a simple blood test would enable early diagnostics of cancer at a relatively low cost,” Soriot concluded.

Public-private partnerships and innovative healthcare models could further improve accessibility and cost-efficiency, helping transform global healthcare systems.

This applies beyond just healthcare. Mike Sicilia, Executive Vice President of Oracle, stated: “At the heart of every AI strategy is a data strategy. Helping governments vectorize and aggregate the data is the first step in applied AI, particularly when tailoring it to specific citizen services.”

AI applications in education were also a major focus at the Summit. David Baszucki, CEO of Roblox, explored the potential of AI in educating young users through interactive experiences on the platform. He also emphasized the importance of balancing social connectivity and safety on digital platforms.

He added: “We are at a place where it is way beyond what we imagined. In 20 years, I’m expecting an amazing amount of learning on the platform—for instance, interacting with virtual historical characters.”

Global economic challenges and financial cooperation

In parallel discussions, Kristalina Georgieva, Managing Director of the IMF, alongside finance ministers, international officials, and economic experts, explored the challenges facing the multilateral cooperation system, including rising nationalist and geopolitical trends, climate change, and economic inequality.

Speakers highlighted the need for innovative financing mechanisms and an expanded global financial safety net to address economic crises and support developing countries.

They also underlined the role of technology in strengthening financial systems, aligning global networks to protect against economic crises, and building sustainable frameworks for debt management in vulnerable economies.

For more information, visit worldgovernmentsummit.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250214293771/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye